Details for Patent: 8,435,502

Which drugs does patent 8,435,502 protect, and when does it expire?

Patent 8,435,502 protects DIFFERIN and is included in one NDA.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 8,435,502

Title:	Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers
Abstract:	Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Inventor(s):	Mallard; Claire (Mougins, FR), Ferrara; Eve (Valbonne, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	13/171,872
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,435,502

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	DIFFERIN	adapalene	LOTION;TOPICAL	022502-001	Mar 17, 2010		DISCN	Yes	No			Y			TREATMENT OF ACNE

Foreign Priority and PCT Information for Patent: 8,435,502

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	05 09493	Sep 16, 2005

International Family Members for US Patent 8,435,502

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057866
Australia	2006290364
Brazil	PI0617045
Canada	2622468